Evolution of Antimicrobial Resistance and Implications for Therapy in Respiratory Infections
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 4505
Special Issue Editor
2. The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Interests: healthcare acquired infections; zoonoses; respiratory tract infections; travel medicine
Special Issue Information
Dear Colleagues,
Respiratory infections in humans, caused by viruses, bacteria and fungi, are amongst the most common burdens on human health, in both the community and healthcare settings. Over the last decades, we have witnessed the spread of antimicrobial resistance (AMR) among community microorganisms such as community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) and Mycobacterium tuberculosis, we well as the overwhelming surge of multidrug-resistant (MDR) Enterobacterales and non-fermenters bacteria acquired in healthcare facilities, especially among critically ill patients.
Viral pandemics such as Influenzae A (H1N1pdm09) and the recent SARS-CoV-2 have amplified outbreaks of MDR bacterial cross-infections within facilities across the globe. MDR and pan-drug-resistant Pseudomonas aeruginosa, Carbapenem-resistant Acinetobacter baumannii, carbapenemase-producing Enterobacterales (CPE), MRSA, as well as resistant fungi such as Candida auris and Aspergillus spp, are now commonly seen and pose great danger to human lives in intensive care units.
This Special Issue of Antibiotics invites researchers to submit work on the evolution and development of AMR among respiratory pathogens acquired in the community or in healthcare facilities, the epidemiology of acquired and inherent AMR among respiratory pathogens, as well new diagnostic tools and therapy implications designed to confront it, including the use of existing and new antimicrobial drugs.
Dr. Regev Cohen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimicrobial resistance
- multidrug-resistant organisms
- respiratory infections
- healthcare-associated infections
- community-acquired infections
- pseudomonas aeruginosa
- acinetobacter baumannii
- carbapenem-resistant enterobacterales
- MRSA
- fungal infection
- candida auris
- apergillus spp
